A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Transfusion

• Publication date

  2008-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1537-2995.2008.01643.xPMID 18346019
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use

  2009cited by this paper
• A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia.

  2009cited by this paper
• Introductory Statistics with R

  2009cited by this paper
• An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment

  2008cited by this paper
• New strategies for the optimal use of platelet transfusions.

  2008cited by this paper
• Patient and product factors affecting platelet transfusion results

  2008cited by this paper
• Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007

  2008cited by this paper
• The surgical application of point‐of‐care haemostasis and platelet function testing

  2008cited by this paper
• Pathogen inactivation: making decisions about new technologies

  2007cited by this paper
• Development of a sensitive real-time reverse transcriptase PCR assay with an internal control to detect and quantify chikungunya virus.

  2007cited by this paper
• A major epidemic of chikungunya virus infection on Reunion Island, France, 2005-2006.

  2007cited by this paper
• The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy‐coat platelets

  2007cited by this paper
• In vitro evaluation of platelet concentrates during storage: Platelet counts and markers of platelet destruction.

  2007cited by this paper
• Evidence-based platelet transfusion guidelines.

  2007cited by this paper
• Blood Manufacturing: Component Preparation, Storage, and Transportation

  2007cited by this paper
• Laboratory capacity for detection of chikungunya virus infections in Europe.

  2007cited by this paper
• Pathogen inactivation: making decisions about new technologies – preliminary report of a consensus conference

  2007cited by this paper
• Genome Microevolution of Chikungunya Viruses Causing the Indian Ocean Outbreak

  2006cited by this paper
• A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma.

  2006cited by this paper
• Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light

  2006cited by this paper
• The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia.

  2006cited by this paper
• Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy

  2006cited by this paper
• Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients

  2006cited by this paper
• Chikungunya risk assessment for Europe: recommendations for action.

  2006cited by this paper
• Chikungunya fever diagnosed among international travelers--United States, 2005-2006.

  2006cited by this paper
• Imported cases of chikungunya in metropolitan France, April 2005 - February 2006.

  2006cited by this paper
• Imported cases of chikungunya in metropolitan France: update to June 2006.

  2006cited by this paper
• Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial

  2005cited by this paper
• Bacterial detection of platelets: current problems and possible resolutions.

  2005cited by this paper
• A mini-review on platelet refractoriness.

  2005cited by this paper
• Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients.

  2005cited by this paper
• Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long‐wavelength ultraviolet light

  2005cited by this paper
• Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set

  2005cited by this paper
• Quantification of human platelet antigen‐1a antibodies with the monoclonal antibody immobilization of platelet antigens procedure

  2005cited by this paper
• Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers

  2004cited by this paper
• Low‐dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design

  2004cited by this paper
• Routine use of platelet components prepared with photochemical treatment (INTERCEPT platelets): Impact on clinical outcomes and costs.

  2004cited by this paper
• Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.

  2004cited by this paper
• Thrombelastography monitoring of platelet substitution therapy and rFVIIa administration in haemato-oncological patients with severe thrombocytopenia.

  2004cited by this paper
• Relationship between platelet count and bleeding risk in thrombocytopenic patients.

  2004cited by this paper
• Factors influencing moderate to severe reactions to PLT transfusions: experience of the TRAP multicenter clinical trial

  2003cited by this paper
• Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.

  2003cited by this paper
• Prophylactic platelet transfusions: which dose is the best dose? A review of the literature.

  2003cited by this paper
• Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998

  2002cited by this paper
• Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions.

  2002cited by this paper
• A randomized controlled trial comparing the frequency of acute reactions to plasma‐removed platelets and prestorage WBC‐reduced platelets

  2002cited by this paper
• 5 – Data Acquisition

  2002cited by this paper
• Blood Banking and Transfusion Medicine

  2002cited by this paper
• Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.

  2001cited by this paper
• Mixed-Effects Models in S and S-PLUS

  2001cited by this paper
• Role of methylene blue‐treated or fresh‐frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura

  2001cited by this paper
• The acute respiratory distress syndrome.

  2000cited by this paper
• Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study

  2000cited by this paper
• Clinical and laboratory factors that affect the post-transfusion platelet increment.

  2000cited by this paper
• Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution

  1999cited by this paper
• Prevention of transfusion-associated graft-versus-host disease by photochemical treatment.

  1999cited by this paper
• An Introduction to the Bootstrap

  1995cited by this paper
• The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.

  1994cited by this paper
• The role of the plasma from platelet concentrates in transfusion reactions.

  1994cited by this paper
• A prospective study to identify the risk factors associated with acute reactions to platelet and red cell transfusions

  1993cited by this paper
• Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions.

  1991cited by this paper
• Factors influencing 20‐hour increments after platelet transfusion

  1991cited by this paper
• Febrile reactions after platelet transfusion: the effect of single versus multiple donors

  1990cited by this paper
• Blood transfusion in Europe

  1990cited by this paper
• A formula to estimate the approximate surface area if height and weight be known

  1989cited by this paper
• Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement

  1985cited by this paper
• Thrombocytopenia: mechanisms and management of defects in platelet production.

  1978cited by this paper
• Contrasting effects of rabbit and human platelets on chikungunya virus infectivity.

  1977cited by this paper
• Stabilization of chikungunya virus infectivity by human blood platelets.

  1970cited by this paper
• The quantitative relation between platelet count and hemorrhage in patients with acute leukemia.

  1962cited by this paper

• Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7‐day storage

  2023cites this paper
• Multinational Analysis of Children Transfused With Pathogen Inactivated Platelets.

  2022cites this paper
• Pathogen‐reduced platelets in pediatric and neonatal patients: Demographics, transfusion rates, and transfusion reactions

  2021cites this paper
• Clinical Uses of Blood Components

  2021cites this paper
• Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light

  2020cites this paper
• Transfusion-Transmitted Infections Reported to the National Healthcare Safety Network Hemovigilance Module.

  2019cites this paper
• Culture-Derived Human Platelets for Clinical Transfusion

  2019cites this paper
• Clinical impact of amotosalen‐ultraviolet A pathogen‐inactivated platelets stored for up to 7 days

  2019cites this paper
• Platelet Transfusion Medicine

  2019cites this paper
• Blood Donation

  2019cites this paper
• Platelet transfusion associated risks and improvement of platelet transfusion safety with Amotosalen/UVA pathogen inactivation technology

  2018cites this paper
• Pathogen inactivation/reduction technologies for platelet transfusion: Where do we stand?

  2018cites this paper
• Nationwide Implementation of Pathogen Inactivation for All Platelet Concentrates in Switzerland

  2018cites this paper
• Działalność jednostek organizacyjnych służby krwi w Polsce w 2017 roku

  2018cites this paper
• Pathogen-reduced platelets for the prevention of bleeding.

  2017cites this paper
• Patient outcomes and amotosalen/UVA‐treated platelet utilization in massively transfused patients

  2017cites this paper
• Indications for and complications of transfusion and the management of gynecologic malignancies.

  2017cites this paper
• Neonatal Platelet Transfusions and Future Areas of Research.

  2016cites this paper
• Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation

  2016cites this paper
• Pathogen Inactivation Technologies: The Advent of Pathogen-Reduced Blood Components to Reduce Blood Safety Risk.

  2016cites this paper
• The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen‐ultraviolet A pathogen reduction treatment model

  2016cites this paper
• Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion‐transmitted bacterial strains

  2015cites this paper
• Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions

  2015cites this paper
• Practical issues that should be considered when planning the implementation of pathogen reduction technology for plateletpheresis.

  2015cites this paper
• A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen–UVA photochemical treatment

  2015cites this paper
• In vitro affinity reduction of biologic response modifiers from production buffy coat platelets exposed to recombinant protein receptors

  2015cites this paper
• Technical challenges in human islet isolation

  2015cites this paper
• Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation

  2015cites this paper
• Supernatants from stored red blood cell (RBC) units, but not RBC‐derived microvesicles, suppress monocyte function in vitro

  2015cites this paper
• Amotosalen‐HCl‐UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin‐27, the cytokines that generally associate with serious adverse events

  2015cites this paper
• Solvent/detergent plasma: pharmaceutical characteristics and clinical experience

  2014cites this paper
• Pathogen reduction technologies

  2014cites this paper
• Pathogen Inactivation Technologies for Cellular Blood Components: an Update

  2014cites this paper
• Reducing the financial impact of pathogen inactivation technology for platelet components: our experience

  2014cites this paper
• Comparison of transfusion efficacy of amotosalen‐based pathogen‐reduced platelet components and gamma‐irradiated platelet components

  2013cites this paper
• OPINION Pathogen inactivation: coming of age

  2013cites this paper
• Current methods for the reduction of blood-borne pathogens: a comprehensive literature review.

  2013cites this paper
• A patient‐oriented risk–benefit analysis of pathogen‐inactivated blood components: application to apheresis platelets in the United States

  2013cites this paper
• Update on the use of pathogen‐reduced human plasma and platelet concentrates

  2013cites this paper
• Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.

  2013cites this paper
• Pathogen inactivation: coming of age

  2013cites this paper
• Pathogen Reduction Technologies: The Best Solution for Safer Blood?

  2013cites this paper
• Model Calculations to Quantify Clinical and Economic Effects of Pathogen Inactivation in Platelet Concentrates

  2013cites this paper
• Pathogen-reduced platelets for the prevention of bleeding.

  2013cites this paper
• Component pathogen inactivation: a critical review

  2013cites this paper
• Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation

  2013cites this paper
• Proteomic analysis of Intercept-treated platelets.

  2012cites this paper
• Oxygen measurements in platelet fluids – a new non‐invasive method to detect bacterial contaminations in platelets

  2012cites this paper
• Meta‐analysis of the studies of bleeding complications of platelets pathogen‐reduced with the Intercept system

  2012cites this paper
• Proteomics of blood and derived products: what’s next?

  2011cites this paper
• Pathogen Inactivation of Human Serum Facilitates its Clinical Use for Islet Cell Culture and Subsequent Transplantation

  2011cites this paper
• Evaluation of platelet transfusion clinical trials

  2011cites this paper
• role of platelet-derived soluble CD40 ligand Platelet components associated with acute transfusion reactions: the

  2011cites this paper
• Clinical Uses of Blood Components

  2011cites this paper
• Safety and clinical efficacy of platelet components prepared with pathogen inactivation in routine use for thrombocytopenic patients

  2011cites this paper
• Determination of acute lung injury after repeated platelet transfusions.

  2011cites this paper
• Challenges in testing for platelet‐related adverse events

  2011cites this paper
• SEPTIC SHOCK CAUSED BY PLATELET CONCENTRATE CONTAMINATED WITH SERRATIA MARCESCENS: A CASE REPORT

  2011cites this paper
• [Pathogen reduction of blood components: from financial issues to possible long-term consequences].

  2011cites this paper
• Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis

  2011cites this paper
• [Pathogen reduction for platelets: available techniques and recent developments].

  2011influential citation
• Réduction de pathogènes des concentrés de plaquettes : techniques existantes et en développement

  2011cites this paper
• Meta‐analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen‐reduced platelets

  2011cites this paper
• Inactivation des pathogènes des produits sanguins labiles : entre enjeux financiers et conséquences possibles à long terme

  2011cites this paper
• The extent of amotosalen photodegradation during photochemical treatment of platelet components correlates with the level of pathogen inactivation

  2011cites this paper
• Pathogen Inactivation of Platelet and Plasma Blood Components for Transfusion Using the INTERCEPT Blood SystemTM

  2011cites this paper
• Current concepts in serological testing – TTID

  2011cites this paper
• Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study.

  2011cites this paper
• Risk-Reduction Strategies for Platelet Transfusion in the United States

  2011cites this paper
• Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3‐year period

  2011cites this paper
• Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction

  2010cites this paper
• A systematic assessment of the quality of reporting for platelet transfusion studies

  2010cites this paper
• Pathogen inactivation of platelet concentrates

  2010cites this paper
• Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC.

  2010cites this paper
• Current debate on pathogen inactivation of platelet concentrates--to use or not to use?

  2010cites this paper
• In vitro and in vivo evaluation of apheresis platelets stored for 5 days in 65% platelet additive solution/35% plasma

  2010cites this paper
• Blood Still Kills: Six Strategies to Further Reduce Allogeneic Blood Transfusion-Related Mortality

  2010cites this paper
• The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.

  2010cites this paper
• An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment

  2010cites this paper
• The usefulness of pathogen inactivation during an outbreak of the new strain of influenza (H1N1).

  2010cites this paper
• Improving blood donor screening by nucleic acid technology (NAT)

  2010cites this paper
• Pathogen inactivation/reduction of platelet concentrates: turning theory into practice

  2010cites this paper
• Bacterial Contamination of Platelet Concentrates: Perspectives for the Future

  2010cites this paper
• Durch Blut übertragbare Infektionskrankheiten

  2010cites this paper
• Kills 99% of known germs

  2010cites this paper
• Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion

  2009cites this paper
• Clinical trials for pathogen reduction in transfusion medicine: a review.

  2009cites this paper
• Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop

  2009cites this paper
• Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products

  2009cites this paper
• BLOOD COMPONENTS: Screening of single‐donor apheresis platelets for bacterial contamination: the PASSPORT study results

  2009cites this paper
• Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use

  2009cites this paper
• Translational research: an important integrated paradigm for transfusion medicine

  2009cites this paper
• Immunologie plaquettaire et réponse immune

  2009cites this paper
• Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation

  2009cites this paper
• Emerging infectious disease agents and their potential threat to transfusion safety

  2009cites this paper
• [Platelet immunology and the immune response].

  2009cites this paper
• Frequency of bacterial contamination of platelet concentrates before and after introduction of diversion method in Japan

  2009cites this paper
• Assessment of safety in neonates for transfusion of platelets and plasma prepared with amotosalen photochemical pathogen inactivation treatment by a 1‐month intravenous toxicity study in neonatal rats

  2009cites this paper
• Reply

  2009cites this paper
• Do human gammadelta T cells respond to M tuberculosis protein antigens?

  2008cites this paper